Dr. Weidong Yu on the Future of the Eye Care Industry

eye care, eye consult, doctor

Dry eyes are a common problem, and studies suggest that they are becoming more and more common in the digital age. Through his extensive research, Dr. Weidong Yu has discovered that the global market around Dry Eye Syndrome (DES) will grow from 3.7 billion in 2019 to 5.1 billion in 2025.

This is just one area of the industry they expect to see grow over the next few years. According to Dr. Yu, the global market for myopia from will grow from 9.27 billion to 13.84 billion, and the global market for eye diseases (glaucoma, cataracts, age-related macular degeneration, and diabetic retinopathy) from 31 billion to 41.5 billion.

Dr. Yu attributes this market increase to a significant increase in screen time. The longer we work in front of a computer, check our phones, or watch TV, the dryer our eyes become, and the greater the risk to our vision health. By the year 2030, Dr. Yu estimates that 50% of the world will require glasses for their sight due to the increase in screen time.

This is an alarming figure, but Dr. Yu urges action over hopelessness. There are measures we can take to improve our vision and protect our eyes from the harmful effects of extended screen usage.
Dr. Weidong Yu has been fighting dry eye and rare eye diseases for over two decades.

Dr. Yu is widely recognized as one of Canada’s premiere Doctors of Traditional Chinese Medicine. He is an entrepreneur who is changing the world by bringing improved sight to those affected by the digital age. Over the past 21 years, Dr. Yu has successfully treated more than 800 worldwide cases of Retinitis Pigmentosa (RP), a disease previously thought to be untreatable.

In conquering this previously unvanquished threat, Dr. Yu has given hope and renewed the quality of life of many of those struggling with the disease. Now, Dr. Yu has developed an AI-based natural vision wellness system that he hopes will be used to enhance vision treatment for Retinitis Pigmentosa patients across the globe.

Dr. Yu hopes to improve vision treatment worldwide with Wellspring AI.

One of the most difficult things about treating Retinitis Pigmentosa is the lack of clear clinical treatment protocols. Before Dr. Yu, there was no set path for treatment. This is what he hopes to change with the forthcoming Wellspring AI, currently in development at the Wellspring Clinic.

Wellspring AI is a new system intended to reshape how we treat Retinitis Pigmentosa. The design process will begin with Dr. Yu’s clinical experience and remedies being translated into an AI-mediated clinical system. The Wellspring AI clinical system will allow Wellspring Vision Care centers and affiliated clinics worldwide to develop clinical treatment protocols based on Dr. Yu’s historical cases of RP patients.

The team hopes that, when completed, this system will light the way for providers to treat Retinitis Pigmentosa with more knowledge and greater confidence than ever before.
Artificial intelligence might be the next big thing in vision care.

Dr. Yu believes that artificial intelligence will play a big role in the future of eye care. He estimates that by 2030, AI-mediated clinical treatment systems will be developed for other eye diseases, such as age-related macular degeneration, glaucoma, diabetic retinopathy, and viral optic neuritis.

Dr. Yu has a bright vision for the future of the eye care industry.

With technological advancements like artificial intelligence technology presenting a wealth of benefits that we’ve only just begun to discover, the eye care industry is likely to see many improvements in the coming years. These developments would benefit both the providers and their patients; with Dr. Yu’s commitment to building a better industry, his vision is likely to become a reality.

Find Dr. Weidong Yu on LinkedIn and Instagram. Learn more about the Wellspring Clinic for Holistic Medicine by visiting their website.

This is a Contributor Post. Opinions expressed here are opinions of the Contributor. Influencive does not endorse or review brands mentioned; does not and cannot investigate relationships with brands, products, and people mentioned and is up to the Contributor to disclose. Contributors, amongst other accounts and articles may be professional fee-based.